No connection

Search Results

ARQT vs ITGR

ARQT
Arcutis Biotherapeutics, Inc.
BEARISH
Price
$22.75
Market Cap
$2.82B
Sector
Healthcare
AI Confidence
85%
ITGR
Integer Holdings Corporation
NEUTRAL
Price
$84.64
Market Cap
$2.91B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ARQT
--
ITGR
29.29
Forward P/E
ARQT
17.79
ITGR
11.71
P/B Ratio
ARQT
14.81
ITGR
1.66
P/S Ratio
ARQT
7.5
ITGR
1.57
EV/EBITDA
ARQT
-359.13
ITGR
11.17

Profitability

Gross Margin
ARQT
90.24%
ITGR
27.39%
Operating Margin
ARQT
14.2%
ITGR
12.79%
Profit Margin
ARQT
-4.29%
ITGR
5.55%
ROE
ARQT
-9.3%
ITGR
6.11%
ROA
ARQT
-1.96%
ITGR
4.75%

Growth

Revenue Growth
ARQT
81.5%
ITGR
5.0%
Earnings Growth
ARQT
--
ITGR
52.9%

Financial Health

Debt/Equity
ARQT
0.6
ITGR
0.75
Current Ratio
ARQT
3.17
ITGR
3.32
Quick Ratio
ARQT
2.83
ITGR
2.05

Dividends

Dividend Yield
ARQT
--
ITGR
--
Payout Ratio
ARQT
0.0%
ITGR
0.0%

AI Verdict

ARQT BEARISH

ARQT's Piotroski F-Score of 1/9 indicates severe financial distress, with weak profitability, negative ROE and ROA, and no dividend, signaling poor operational health. Despite strong revenue growth of 81.5% YoY and a forward P/E of 17.79, the company remains unprofitable with a negative profit margin of -4.29% and no intrinsic value or Graham Number available. Insider selling totaling $5.12M in the last six months, including significant sales by the CEO and directors, reinforces bearish sentiment. The stock trades at a premium to its fundamentals, with a Price/Sales of 7.50 and Price/Book of 14.81, suggesting overvaluation relative to earnings and book value. Analysts' strong_buy consensus appears disconnected from the underlying financial deterioration.

Strengths
81.5% YoY revenue growth indicates strong market expansion and product demand
High gross margin of 90.24% reflects efficient production and pricing power
Strong current and quick ratios (3.17 and 2.83) suggest solid short-term liquidity
Risks
Piotroski F-Score of 1/9 signals extreme financial weakness and operational instability
Negative ROE (-9.30%) and ROA (-1.96%) indicate poor capital efficiency and unprofitability
Insider selling of $5.12M in 6 months, including CEO and directors, raises governance concerns
ITGR NEUTRAL

Integer Holdings (ITGR) presents a dichotomy between strong forward-looking earnings potential and weak current market sentiment. The Piotroski F-Score of 4/9 indicates stable but not robust financial health, while the stock is currently trading almost exactly at its growth-based intrinsic value of $85.26, leaving no margin of safety. While the trailing P/E is high, the Forward P/E of 11.71 and explosive YoY earnings growth of 52.9% suggest a significant valuation correction is underway. However, a bearish technical trend and negative insider sentiment temper the bullish analyst consensus.

Strengths
Exceptional short-term liquidity with a Current Ratio of 3.32
Strong earnings acceleration with 52.9% YoY growth
Attractive Forward P/E (11.71) compared to trailing P/E (29.29)
Risks
Lack of margin of safety as price ($84.64) equals intrinsic value ($85.26)
Stagnant revenue growth (5% YoY) suggesting earnings growth is driven by cost-cutting rather than expansion
Bearish technical trend (0/100) and negative insider sentiment

Compare Another Pair

ARQT vs ITGR: Head-to-Head Comparison

This page compares Arcutis Biotherapeutics, Inc. (ARQT) and Integer Holdings Corporation (ITGR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile